NEW YORK (GenomeWeb News) – BioTheranostics today said that it has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerTypeID molecular cancer classifier.

Tufts has more than 1 million members.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.